223 related articles for article (PubMed ID: 22332960)
41. Rufinamide.
Arroyo S
Neurotherapeutics; 2007 Jan; 4(1):155-62. PubMed ID: 17199032
[TBL] [Abstract][Full Text] [Related]
42. Cognitive, adaptive, and behavioral effects of adjunctive rufinamide in Lennox-Gastaut syndrome: A prospective observational clinical study.
Operto FF; Verrotti A; Marrelli A; Ciuffini R; Coppola G; Pastorino GMG; Striano P; Sole M; Zucca C; Manfredi V; Città S; Elia M
Epilepsy Behav; 2020 Nov; 112():107445. PubMed ID: 32920379
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022.
Arzimanoglou A; Pringsheim M; Kluger GJ; Genton P; Perdomo C; Malhotra M
Epilepsy Behav; 2021 Sep; 124():108275. PubMed ID: 34509883
[TBL] [Abstract][Full Text] [Related]
44. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome.
Ng YT; Conry JA; Drummond R; Stolle J; Weinberg MA;
Neurology; 2011 Oct; 77(15):1473-81. PubMed ID: 21956725
[TBL] [Abstract][Full Text] [Related]
45. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
46. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
[TBL] [Abstract][Full Text] [Related]
47. Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion.
Sankar R; Chez M; Pina-Garza JE; Dixon-Salazar T; Flamini JR; Hyslop A; McGoldrick P; Millichap JJ; Resnick T; Rho JM; Wolf S
Seizure; 2023 Aug; 110():42-57. PubMed ID: 37321047
[TBL] [Abstract][Full Text] [Related]
48. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Wijnen B; Armstrong N; Ramaekers B; Witlox W; Westwood M; Fayter D; Ryder S; Buksnys T; Worthy G; Misso K; Grimm S; Kleijnen J; Joore M
Pharmacoeconomics; 2020 Oct; 38(10):1043-1053. PubMed ID: 32514751
[TBL] [Abstract][Full Text] [Related]
49. Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome.
Neuberger EE; Carlson JJ; Veenstra DL
Pharmacoeconomics; 2020 Nov; 38(11):1237-1245. PubMed ID: 32715412
[TBL] [Abstract][Full Text] [Related]
50. Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients.
Caraballo RH; Pociecha J; Reyes G; Espeche A; Galichio S; Fasulo L; Semprino M
Epilepsy Behav; 2020 Jul; 108():107074. PubMed ID: 32334364
[TBL] [Abstract][Full Text] [Related]
51. Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.
Ferrie CD
Expert Rev Neurother; 2010 Jun; 10(6):851-60. PubMed ID: 20518600
[TBL] [Abstract][Full Text] [Related]
52. Lennox-Gastaut syndrome: a comprehensive review.
Asadi-Pooya AA
Neurol Sci; 2018 Mar; 39(3):403-414. PubMed ID: 29124439
[TBL] [Abstract][Full Text] [Related]
53. [Lennox-Gastaut syndrome--course and treatment].
Lund C; Brodtkorb E; Nakken KO
Tidsskr Nor Laegeforen; 2011 Jan; 131(1):24-7. PubMed ID: 21233883
[TBL] [Abstract][Full Text] [Related]
54. [Short-term efficacy and safety of rufinamide for Lennox-Gastaut syndrome].
Takayama R; Fukumura S; Minagawa K; Watanabe T
No To Hattatsu; 2016 Sep; 48(5):322-6. PubMed ID: 30010275
[TBL] [Abstract][Full Text] [Related]
55. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
Lo SH; Lloyd A; Marshall J; Vyas K
Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of rufinamide in childhood refractory epilepsy.
Yıldız EP; Hızlı Z; Bektaş G; Ulak-Özkan M; Tatlı B; Aydınlı N; Çalışkan M; Özmen M
Turk J Pediatr; 2018; 60(3):238-243. PubMed ID: 30511535
[TBL] [Abstract][Full Text] [Related]
57. Rufinamide: a new anti-epileptic medication.
Hakimian S; Cheng-Hakimian A; Anderson GD; Miller JW
Expert Opin Pharmacother; 2007 Aug; 8(12):1931-40. PubMed ID: 17696794
[TBL] [Abstract][Full Text] [Related]
58. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis.
Zhang L; Wang J; Wang C
Dev Med Child Neurol; 2022 Mar; 64(3):305-313. PubMed ID: 34590711
[TBL] [Abstract][Full Text] [Related]
60. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
